$59.44
Live
0.4%
Downside
Day's Volatility :1.91%
Upside
1.51%
18.91%
Downside
52 Weeks Volatility :31.93%
Upside
16.06%
Period | Ani Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -2.84% | 3.6% | 0.0% |
6 Months | -8.09% | 10.2% | 0.0% |
1 Year | 6.07% | 19.6% | 0.0% |
3 Years | 59.47% | 16.8% | -23.0% |
Market Capitalization | 1.3B |
Book Value | $23.31 |
Earnings Per Share (EPS) | 1.19 |
PE Ratio | 50.68 |
PEG Ratio | 1.06 |
Wall Street Target Price | 80.0 |
Profit Margin | 5.01% |
Operating Margin TTM | 6.54% |
Return On Assets TTM | 3.38% |
Return On Equity TTM | 5.9% |
Revenue TTM | 539.0M |
Revenue Per Share TTM | 28.24 |
Quarterly Revenue Growth YOY | 18.4% |
Gross Profit TTM | 177.6M |
EBITDA | 108.0M |
Diluted Eps TTM | 1.19 |
Quarterly Earnings Growth YOY | 13.82 |
EPS Estimate Current Year | 4.7 |
EPS Estimate Next Year | 5.25 |
EPS Estimate Current Quarter | 0.95 |
EPS Estimate Next Quarter | 1.08 |
What analysts predicted
Upside of 34.59%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 201.6M | ↑ 13.99% |
Net Income | 15.5M | ↓ 1539.96% |
Net Profit Margin | 7.69% | ↑ 8.3% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 206.5M | ↑ 2.47% |
Net Income | 6.1M | ↓ 60.67% |
Net Profit Margin | 2.95% | ↓ 4.74% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 208.5M | ↑ 0.93% |
Net Income | -22.5M | ↓ 470.0% |
Net Profit Margin | -10.82% | ↓ 13.77% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 216.1M | ↑ 3.67% |
Net Income | -42.6M | ↑ 88.94% |
Net Profit Margin | -19.71% | ↓ 8.89% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 316.4M | ↑ 46.38% |
Net Income | -47.9M | ↑ 12.42% |
Net Profit Margin | -15.14% | ↑ 4.57% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 486.8M | ↑ 53.87% |
Net Income | 18.8M | ↓ 139.21% |
Net Profit Margin | 3.86% | ↑ 19.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 106.8M | ↑ 13.32% |
Net Income | 1.4M | ↓ 133.91% |
Net Profit Margin | 1.35% | ↑ 5.85% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 116.5M | ↑ 9.14% |
Net Income | 6.2M | ↑ 333.98% |
Net Profit Margin | 5.36% | ↑ 4.01% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 131.8M | ↑ 13.11% |
Net Income | 9.9M | ↑ 59.17% |
Net Profit Margin | 7.54% | ↑ 2.18% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 131.7M | ↓ 0.13% |
Net Income | 1.2M | ↓ 88.38% |
Net Profit Margin | 0.88% | ↓ 6.66% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 137.4M | ↑ 4.39% |
Net Income | 18.2M | ↑ 1476.36% |
Net Profit Margin | 13.25% | ↑ 12.37% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 138.0M | ↑ 0.44% |
Net Income | -2.3M | ↓ 112.56% |
Net Profit Margin | -1.66% | ↓ 14.91% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 430.6M | ↑ 4.48% |
Total Liabilities | 233.3M | ↓ 1.7% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 456.8M | ↑ 6.08% |
Total Liabilities | 244.0M | ↑ 4.57% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 461.2M | ↑ 0.96% |
Total Liabilities | 265.5M | ↑ 8.81% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 771.6M | ↑ 67.31% |
Total Liabilities | 412.9M | ↑ 55.51% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 760.1M | ↓ 1.49% |
Total Liabilities | 421.5M | ↑ 2.1% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 904.4M | ↑ 18.99% |
Total Liabilities | 471.7M | ↑ 11.89% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 765.2M | ↑ 0.68% |
Total Liabilities | 425.7M | ↑ 1.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 859.3M | ↑ 12.3% |
Total Liabilities | 424.9M | ↓ 0.21% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 889.9M | ↑ 3.56% |
Total Liabilities | 435.2M | ↑ 2.43% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 904.4M | ↑ 1.63% |
Total Liabilities | 471.7M | ↑ 8.38% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 914.5M | ↑ 1.12% |
Total Liabilities | 462.6M | ↓ 1.93% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 920.8M | ↑ 0.68% |
Total Liabilities | 465.0M | ↑ 0.53% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 67.1M | ↑ 70.16% |
Investing Cash Flow | -27.4M | ↓ 74.65% |
Financing Cash Flow | -27.8M | ↓ 138.44% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 45.6M | ↓ 31.97% |
Investing Cash Flow | -27.5M | ↑ 0.62% |
Financing Cash Flow | 1.3M | ↓ 104.49% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 15.3M | ↓ 66.54% |
Investing Cash Flow | -68.3M | ↑ 148.0% |
Financing Cash Flow | -1.4M | ↓ 215.12% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.3M | ↓ 78.24% |
Investing Cash Flow | -105.5M | ↑ 54.39% |
Financing Cash Flow | 194.6M | ↓ 13622.93% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -31.2M | ↓ 1039.28% |
Investing Cash Flow | -15.7M | ↓ 85.08% |
Financing Cash Flow | -5.1M | ↓ 102.63% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 21.4M | ↓ 586.91% |
Investing Cash Flow | -2.4M | ↓ 25.11% |
Financing Cash Flow | -4.5M | ↑ 795.28% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 20.6M | ↓ 3.72% |
Investing Cash Flow | -6.8M | ↑ 190.1% |
Financing Cash Flow | 80.2M | ↓ 1862.31% |
Sell
Neutral
Buy
Ani Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Ani Pharmaceuticals Inc | 0.38% | -8.09% | 6.07% | 59.47% | -20.52% |
Neurocrine Biosciences Inc. | 0.22% | -11.71% | 9.36% | 13.47% | 21.32% |
Haleon Plc Spon Ads | -5.08% | 20.69% | 22.01% | 36.17% | 36.17% |
Zoetis Inc. | -0.16% | 32.8% | 16.08% | -7.35% | 52.85% |
Viatris Inc. | 2.53% | 4.53% | 31.84% | -16.06% | -28.03% |
Catalent, Inc. | 0.9% | 7.56% | 42.8% | -54.43% | 23.98% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Ani Pharmaceuticals Inc | 50.68 | 50.68 | 1.06 | 4.7 | 0.06 | 0.03 | NA | 23.31 |
Neurocrine Biosciences Inc. | 35.55 | 35.55 | 0.27 | 4.54 | 0.16 | 0.12 | NA | 24.87 |
Haleon Plc Spon Ads | 32.52 | 32.52 | 1.5 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
Zoetis Inc. | 37.9 | 37.9 | 2.64 | 5.83 | 0.49 | 0.14 | 0.01 | 10.94 |
Viatris Inc. | 224.4 | NA | 0.07 | 2.67 | -0.03 | 0.03 | 0.04 | 16.36 |
Catalent, Inc. | 211.02 | NA | 3.02 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Ani Pharmaceuticals Inc | Buy | $1.3B | -20.52% | 50.68 | 5.01% |
Neurocrine Biosciences Inc. | Buy | $11.9B | 21.32% | 35.55 | 16.0% |
Haleon Plc Spon Ads | Buy | $45.6B | 36.17% | 32.52 | 9.66% |
Zoetis Inc. | Buy | $87.6B | 52.85% | 37.9 | 26.29% |
Viatris Inc. | Hold | $14.0B | -28.03% | 224.4 | -4.24% |
Catalent, Inc. | Hold | $10.9B | 23.98% | 211.02 | -23.81% |
Insights on Ani Pharmaceuticals Inc
Revenue is up for the last 3 quarters, 131.65M → 138.04M (in $), with an average increase of 2.3% per quarter
Netprofit is down for the last 2 quarters, 18.20M → -2.28M (in $), with an average decrease of 112.6% per quarter
In the last 1 year, Catalent, Inc. has given 43.0% return, outperforming this stock by 38.0%
BlackRock Inc
Vanguard Group Inc
State Street Corp
Dimensional Fund Advisors, Inc.
Rubric Capital Management LP
Global Alpha Capital Management Ltd.
ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.
Organization | Ani Pharmaceuticals Inc |
Employees | 642 |
CEO | Mr. Nikhil Lalwani |
Industry | Health Technology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$59.44
-1.44%
Invesco Bulletshares 2025 Hi
$59.44
-1.44%
Schwab International Dividend Equity Etf
$59.44
-1.44%
Blockchain Coinvestors Acquisition Corp.
$59.44
-1.44%
Allgiant Travel Company
$59.44
-1.44%
Rogers Corp
$59.44
-1.44%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$59.44
-1.44%
Iheartmedia
$59.44
-1.44%
Lightpath Technologies Inc
$59.44
-1.44%